EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel insight into histological and molecular astrocytoma, IDH ‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors

Wenlin Chen, Siying Guo iD, Yaning Wang iD, Yixin Shi, Xiaopeng Guo, Delin Liu, Yilin Li, Yuekun Wang, Hao Xing, Yu Xia, Junlin Li, Jiaming Wu und 10 weitere

Cancer Medicine · 2023-09 · 12 (18) · 18666-18678

DOI: 10.1002/cam4.6476 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.09.2023. Verfasst von Wenlin Chen und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy o…. Hauptthemen laut MEDLINE: Brain Neoplasms, Astrocytoma, Central Nervous System Neoplasms, Glioblastoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The latest fifth edition of the World Health Organization (WHO) classification of the central nervous system (CNS) tumors (WHO CNS 5 classification) released in 2021 defined astrocytoma, IDH‐ mutant, Grade 4. However, the understanding of this subtype is still limited. We conducted this study to describe the features of astrocytoma, IDH ‐mutant, Grade 4 and explored the similarities and differences between histological and molecular subtypes.

Methods

Patients who underwent surgery from January 2011 to January 2022, classified as astrocytoma, IDH ‐mutant, Grade 4 were included in this study. Clinical, radiological, histopathological, molecular pathological, and survival data were collected for analysis.

Results

Altogether 33 patients with astrocytoma, IDH ‐mutant, Grade 4 were selected, including 20 with histological and 13 with molecular WHO Grade 4 astrocytoma. Tumor enhancement, intratumoral‐necrosis like presentation, larger peritumoral edema, and more explicit tumor margins were frequently observed in histological WHO Grade 4 astrocytoma. Additionally, molecular WHO Grade 4 astrocytoma showed a tendency for relatively longer overall survival, while a statistical significance was not reached (47 vs. 25 months, p = 0.22). TP53 , CDK6 , and PIK3CA alteration was commonly observed, while PIK3R1 ( p = 0.033 ), Notch1 ( p = 0.027 ), and Mycn (p = 0.027) alterations may affect the overall survival of molecular WHO Grade 4 astrocytomas.

Conclusions

Our study scrutinized IDH ‐mutant, Grade 4 astrocytoma. Therefore, further classification should be considered as the prognosis varied between histological and molecular WHO Grade 4 astrocytomas. Notably, therapies aiming at PIK3R1 , Notch 1 , and Mycn may be beneficial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsAstrocytomaCentral Nervous System NeoplasmsGlioblastomaHumansN-Myc Proto-Oncogene ProteinIsocitrate DehydrogenaseMutationWorld Health Organization

Stichwörter der Autor:innen

2021 WHO classification of central nervous system tumorsGrade 4IDH-mutantastrocytomagliomamolecular alterationradiological characteristics

Substanzen

N-Myc Proto-Oncogene ProteinIsocitrate Dehydrogenase

Autor:innen und Institutionen

  • Department of Neurosurgery, Center for Malignant Brain Tumors, National Glioma MDT Alliance, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • Eight-year Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
  • China Anti-Cancer Association Specialty Committee of Glioma, Beijing, China.
  • 4+4 Medical Doctor Program, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

ORCID-Profile: Siying Guo, Yaning Wang, Yu Wang

Förderung

  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Chen, W., Guo, S., Wang, Y., Shi, Y., Guo, X., Liu, D., Li, Y., Wang, Y., Xing, H., Xia, Y., Li, J., Wu, J., Liang, T., Wang, H., Liu, Q., Jin, S., Qu, T., Li, H., Yang, T., …, & Ma, W. (2023). Novel insight into histological and molecular astrocytoma, IDH ‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors. Cancer Medicine, 12(18), 18666-18678. https://doi.org/10.1002/cam4.6476

Vancouver

Chen W, Guo S, Wang Y, Shi Y, Guo X, Liu D, et al. Novel insight into histological and molecular astrocytoma, IDH ‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors. Cancer Medicine. 2023;12(18):18666-18678. doi:10.1002/cam4.6476

BibTeX
@article{Chen2023,
  author = {Chen, Wenlin and Guo, Siying and Wang, Yaning and Shi, Yixin and Guo, Xiaopeng and Liu, Delin and Li, Yilin and Wang, Yuekun and Xing, Hao and Xia, Yu and Li, Junlin and Wu, Jiaming and Liang, Tingyu and Wang, Hai and Liu, Qianshu and Jin, Shanmu and Qu, Tian and Li, Huanzhang and Yang, Tianrui and Zhang, Kun and Wang, Yu and Ma, Wenbin},
  title = {Novel insight into histological and molecular astrocytoma, IDH ‐mutant, Grade 4 by the updated WHO classification of central nervous system tumors},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {18},
  pages = {18666--18678},
  doi = {10.1002/cam4.6476}
}
Kostenlos starten →